Abstract
Morphea is a fibrosing disorder of the skin without systemic involvement. It can be clinically classified in different forms: circumscribed, linear, generalized, pansclerotic and mixed forms. The pathogenesis is not completely understood. An underlying predisposition and environmental factors are required to develop the disease. No causal treatment for morphea exists. Topical systemic and phototherapy are used. Topical treatments are adequate for limited forms, while phototherapy and systemic treatment are used for the more severe forms of the disease. Corticosteroids are the mainstay of topical treatments. Topical calcipotriol and tacrolimus have been evaluated in open studies and they seem to improve significantly morphea. UVA1 which penetrate deeper in the dermis than narrow-band UVB are usually considered the best option in phototherapy. Methotrexate is the systemic drug which has the best evidences; it can be used in addition to corticosteroids, in particular in severe morphea of young people.
| Original language | English |
|---|---|
| Title of host publication | European Handbook of Dermatological Treatments, Third Edition |
| Publisher | Springer Berlin Heidelberg |
| Pages | 637-642 |
| Number of pages | 6 |
| ISBN (Print) | 9783662451397, 9783662451380 |
| DOIs | |
| Publication status | Published - Jan 1 2015 |
Fingerprint
Keywords
- Localized scleroderma
- Morphea
- Treatment
ASJC Scopus subject areas
- Medicine(all)
Cite this
Morphea (localized scleroderma). / Parodi, Aurora.
European Handbook of Dermatological Treatments, Third Edition. Springer Berlin Heidelberg, 2015. p. 637-642.Research output: Chapter in Book/Report/Conference proceeding › Chapter
}
TY - CHAP
T1 - Morphea (localized scleroderma)
AU - Parodi, Aurora
PY - 2015/1/1
Y1 - 2015/1/1
N2 - Morphea is a fibrosing disorder of the skin without systemic involvement. It can be clinically classified in different forms: circumscribed, linear, generalized, pansclerotic and mixed forms. The pathogenesis is not completely understood. An underlying predisposition and environmental factors are required to develop the disease. No causal treatment for morphea exists. Topical systemic and phototherapy are used. Topical treatments are adequate for limited forms, while phototherapy and systemic treatment are used for the more severe forms of the disease. Corticosteroids are the mainstay of topical treatments. Topical calcipotriol and tacrolimus have been evaluated in open studies and they seem to improve significantly morphea. UVA1 which penetrate deeper in the dermis than narrow-band UVB are usually considered the best option in phototherapy. Methotrexate is the systemic drug which has the best evidences; it can be used in addition to corticosteroids, in particular in severe morphea of young people.
AB - Morphea is a fibrosing disorder of the skin without systemic involvement. It can be clinically classified in different forms: circumscribed, linear, generalized, pansclerotic and mixed forms. The pathogenesis is not completely understood. An underlying predisposition and environmental factors are required to develop the disease. No causal treatment for morphea exists. Topical systemic and phototherapy are used. Topical treatments are adequate for limited forms, while phototherapy and systemic treatment are used for the more severe forms of the disease. Corticosteroids are the mainstay of topical treatments. Topical calcipotriol and tacrolimus have been evaluated in open studies and they seem to improve significantly morphea. UVA1 which penetrate deeper in the dermis than narrow-band UVB are usually considered the best option in phototherapy. Methotrexate is the systemic drug which has the best evidences; it can be used in addition to corticosteroids, in particular in severe morphea of young people.
KW - Localized scleroderma
KW - Morphea
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=84944584889&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84944584889&partnerID=8YFLogxK
U2 - 10.1007/978-3-662-45139-7_64
DO - 10.1007/978-3-662-45139-7_64
M3 - Chapter
AN - SCOPUS:84944584889
SN - 9783662451397
SN - 9783662451380
SP - 637
EP - 642
BT - European Handbook of Dermatological Treatments, Third Edition
PB - Springer Berlin Heidelberg
ER -